Literature DB >> 31737504

Brain metastases from lung cancer with neuropsychiatric symptoms as the first symptoms.

Kai Dong1, Lei Liu2, Zhipeng Yu1, Di Wu3, Qian Zhang1, Xiaoqin Huang1, Jianping Ding1, Haiqing Song1.   

Abstract

BACKGROUND: To investigate the neuropsychiatric symptoms and their treatment and outcomes in lung cancer patients with brain metastases (BM), with an attempt to achieve early detection and prompt management of these symptoms.
METHODS: Ten lung cancer patients (8 males and 2 females) with BMs who were treated in our center from 2013 to 2019 were enrolled in this analysis. Without exception, all 10 patients presented with chief complaints of neuropsychiatric symptoms, and BMs were eventually diagnosed. Appropriate treatments were offered, and all patients were followed up.
RESULTS: Two patients died (case 5 died of sudden massive hemoptysis, and case 6 died after his families refused to receive the invasive treatment). Data on 3- and 5-year survival have been obtained from one patient each. The average follow-up duration was 19.4 months (except that two patients were hospitalized only once, and one patient received the second follow-up visit only 9 days after the first visit).
CONCLUSIONS: The possibility of BM from lung cancer should be considered when a lung cancer patient develops neuropsychiatric symptoms, and timely diagnosis treatment should be arranged accordingly. 2019 Translational Lung Cancer Research. All rights reserved.

Entities:  

Keywords:  Lung cancer; brain metastases (BM); neuropsychiatric symptoms

Year:  2019        PMID: 31737504      PMCID: PMC6835098          DOI: 10.21037/tlcr.2019.10.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  17 in total

1.  Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine?

Authors:  Elizabeth J Buss; Tony J C Wang
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.

Authors:  Fable Zustovich; Alessandra Ferro; Giuseppe Lombardi; Patrizia Farina; Vittorina Zagonel
Journal:  Chemotherapy       Date:  2015-05-20       Impact factor: 2.544

3.  Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.

Authors:  Valerio Nardone; Sara Nanni; Pierpaolo Pastina; Claudia Vinciguerra; Alfonso Cerase; Pierpaolo Correale; Cesare Guida; Antonio Giordano; Paolo Tini; Alfonso Reginelli; Salvatore Cappabianca; Luigi Pirtoli
Journal:  Strahlenther Onkol       Date:  2019-05-23       Impact factor: 3.621

4.  Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.

Authors:  Inan Olmez; Bernadine R Donahue; James S Butler; Yiwu Huang; Philip Rubin; Yiqing Xu
Journal:  Lung Cancer       Date:  2010-03-06       Impact factor: 5.705

5.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

Authors:  L Gaspar; C Scott; M Rotman; S Asbell; T Phillips; T Wasserman; W G McKenna; R Byhardt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

6.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

Authors:  Leo J Schouten; Joost Rutten; Hans A M Huveneers; Albert Twijnstra
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

Review 7.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Laurie E Gaspar; Minesh P Mehta; Roy A Patchell; Stuart H Burri; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

8.  Incidence of brain metastasis at initial presentation of lung cancer.

Authors:  J Lee Villano; Eric B Durbin; Chris Normandeau; Jigisha P Thakkar; Valentina Moirangthem; Faith G Davis
Journal:  Neuro Oncol       Date:  2014-06-02       Impact factor: 12.300

9.  Quantitative and textural analysis of magnetization transfer and diffusion images in the early detection of brain metastases.

Authors:  Nicola L Ainsworth; Mary A McLean; Dominick J O McIntyre; Davina J Honess; Anna M Brown; Susan V Harden; John R Griffiths
Journal:  Magn Reson Med       Date:  2016-06-09       Impact factor: 4.668

10.  Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis.

Authors:  Fei Lu; Yu Hou; Yaoxiong Xia; Lan Li; Li Wang; Ke Cao; Haixia Chen; Li Chang; Wenhui Li
Journal:  Cancer Manag Res       Date:  2019-05-08       Impact factor: 3.989

View more
  2 in total

1.  The LMCD1-AS1/miR-526b-3p/OSBPL5 axis promotes cell proliferation, migration and invasion in non-small cell lung cancer.

Authors:  Rui Hu; Yankai Yu; Haining Wang
Journal:  BMC Pulm Med       Date:  2022-01-09       Impact factor: 3.317

2.  Testis developmental related gene 1 promotes non-small-cell lung cancer through the microRNA-214-5p/Krüppel-like factor 5 axis.

Authors:  Xudong Lu; Nian Zhao; Guangjun Duan; Zhiyong Deng; Yimin Lu
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.